Literature DB >> 18343325

Pharmacologic management of temporomandibular disorders.

Elliot V Hersh1, Ramesh Balasubramaniam, Andres Pinto.   

Abstract

Although there are theoretically numerous pharmacologic targets for relieving temporomandibular disorder (TMD)-associated pains, evidence-based literature clearly establishing the efficacy and safety of drugs in the TMD population is limited at best. This article reviews the pharmacology, toxicology, and research supporting the use of a host of pharmacologic agents that have been used in patients who have TMD, including nonsteroidal anti-inflammatory drugs, corticosteroids, benzodiazepines, nonbenzodiazepine sedative hypnotics, opioids, skeletal muscle relaxants, capsaicin, transdermal lidocaine, antidepressants, and anticonvulsants. Recommendations regarding the proper use of each drug class are also made.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343325     DOI: 10.1016/j.coms.2007.12.005

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  16 in total

1.  Wavelength effect in temporomandibular joint pain: a clinical experience.

Authors:  Carolina M Carvalho; Juliana A de Lacerda; Fernando P dos Santos Neto; Maria Cristina T Cangussu; Aparecida M C Marques; Antônio L B Pinheiro
Journal:  Lasers Med Sci       Date:  2009-06-30       Impact factor: 3.161

2.  Evaluation of low-level laser therapy effectiveness on the pain and masticatory performance of patients with myofascial pain.

Authors:  Mila Leite de Moraes Maia; Maria Amália Gonzaga Ribeiro; Luiz Guilherme Martins Maia; Juliana Stuginski-Barbosa; Yuri Martins Costa; André Luís Porporatti; Paulo César Rodrigues Conti; Leonardo Rigoldi Bonjardim
Journal:  Lasers Med Sci       Date:  2012-11-10       Impact factor: 3.161

Review 3.  Anesthetic Considerations for Patients on Antidepressant Therapy-Part I.

Authors:  Mana Saraghi; Leonard R Golden; Elliot V Hersh
Journal:  Anesth Prog       Date:  2017

Review 4.  Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders.

Authors:  Ashkan Aryaei; Natalia Vapniarsky; Jerry C Hu; Kyriacos A Athanasiou
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 5.  Neuromuscular dentistry: Occlusal diseases and posture.

Authors:  Mohd Toseef Khan; Sanjeev Kumar Verma; Sandhya Maheshwari; Syed Naved Zahid; Prabhat K Chaudhary
Journal:  J Oral Biol Craniofac Res       Date:  2013-04-05

6.  Efficacy of Low-Level Laser, Hard Occlusal Appliance and Conventional Pharmacotherapy in the Management of Myofascial Pain Dysfunction Syndrome; A Preliminary Study.

Authors:  Hassan Azangoo Khiavi; Hooman Ebrahimi; Shamsolmolouk Najafi; Maryam Nakisa; Sareh Habibzadeh; Mina Khayamzadeh; Mohammad Javad Kharazifard
Journal:  J Lasers Med Sci       Date:  2020-01-18

7.  Orofacial pain - an update on diagnosis and management.

Authors:  S Ghurye; R McMillan
Journal:  Br Dent J       Date:  2017-10-27       Impact factor: 1.626

8.  Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.

Authors:  Wen Xu; Yuwei Wu; Yeping Bi; Lei Tan; Yehua Gan; Kewei Wang
Journal:  Mol Pain       Date:  2010-08-27       Impact factor: 3.395

9.  Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.

Authors:  Inna E Tchivileva; Holly Hadgraft; Pei Feng Lim; Massimiliano Di Giosia; Margarete Ribeiro-Dasilva; John H Campbell; Janet Willis; Robert James; Marcus Herman-Giddens; Roger B Fillingim; Richard Ohrbach; Samuel J Arbes; Gary D Slade
Journal:  Pain       Date:  2020-08       Impact factor: 7.926

10.  Profiling the clinical presentation of diagnostic characteristics of a sample of symptomatic TMD patients.

Authors:  Luciana Pimenta e Silva Machado; Marianita Batista de Macedo Nery; Cláudio de Góis Nery; Cláudio Rodrigues Leles
Journal:  BMC Oral Health       Date:  2012-08-02       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.